Insider transactions at Adaptive Biotechnologies
Adaptive Biotechnologies (NASDAQ:ADPT) reported insider activity this month as President and Chief Operating Officer Julie Rubinstein sold a total of 159,243 shares of common stock over a three-day span from March 11 to March 13, 2026. The share sales generated roughly $2.37 million in aggregate proceeds, with execution prices ranging from $12.11 to $14.38 per share.
Breakdown of the trades
On March 11, Rubinstein sold 122,523 shares at $13.17 per share, producing approximately $1.61 million. Additional dispositions executed across March 11, 12 and 13 amounted to 51,780 shares, transacted in the $12.63 to $14.08 price band and yielding roughly $760,430 in proceeds.
Option exercise
Separately, Rubinstein exercised options to acquire 44,166 shares at an exercise price of $6.55 per share, which represents a total cost of $289,287 for those shares. Company filings indicate these sales and the option exercise were carried out under a pre-arranged Rule 10b5-1 trading plan that Rubinstein adopted on November 18, 2025.
Market context
The insider activity takes place while ADPT shares trade at approximately $13.17 and the company maintains a market capitalization of about $2.01 billion. The stock has been volatile in recent sessions, falling 11% over the prior week even after an 81% year-over-year gain.
Valuation signals and analyst commentary
Investment research noted in filings suggests ADPT currently appears overvalued relative to its Fair Value, according to InvestingPro analysis. For readers seeking additional context, the InvestingPro platform is cited as offering expanded coverage, including 12 ProTips and detailed financials, although those materials are outside the scope of this report.
Related quarterly results and analyst responses
In separate disclosures, Adeptus Biotechnologies Corp released fourth-quarter 2025 results that exceeded analyst expectations. The company posted an earnings per share of -$0.09 versus a forecasted -$0.18, and reported $71.7 million in revenue against an expected $59.33 million. That revenue outcome was noted as roughly 20.85% higher than projections.
Following the quarter, several brokerages adjusted their views. BTIG raised its price target to $22, citing strength in the company’s Minimal Residual Disease business, which reported 54% year-over-year growth in the fourth quarter and 46% growth for the full year. TD Cowen increased its target to $21, while Piper Sandler reiterated an Overweight rating and emphasized projected clonoSEQ volume growth of more than 30%.
This article presents reported insider transactions and related company results and analyst actions as disclosed in company filings and research notes. It does not provide investment advice.